Real-world impact of education: treating patients with ipilimumab in a community practice setting

After decades without promising new treatments for advanced and metastatic melanoma, ipilimumab was the first systemic therapy approved for use in this patient population. A fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor T-cell responses, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledezma, Blanca, Heng, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873235/
https://www.ncbi.nlm.nih.gov/pubmed/24379698
http://dx.doi.org/10.2147/CMAR.S52543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873235/
https://www.ncbi.nlm.nih.gov/pubmed/24379698
http://dx.doi.org/10.2147/CMAR.S52543

Ejemplares similares